Biomarkers for the detection of bladder cancer.
In this subject review, a series of morphology-based and molecular markers were compared with urinary cytology for the detection of recurrent urothelial neoplasia. Among the various biomarkers reviewed, the average published sensitivity and specificity for the Bard BTA test was 60% and 77%; the NMP22 Test was 67% and 72%; the telomerase assay was 77% and 85%; and the microsatellite assay was 89% and 100%. DNA ploidy measurements and immunoassays designed to detect keratins, proteins, hyaluronidase, growth factors, cell adhesion molecules, fibrinogen degradation products, cell cycle regulators, and molecular markers were also included. Although the performance features of these biomarkers have varied and the cytologic methods to which they have been compared have not been standardized, several of the procedures have received considerable support from urologists as assisting them in the management of their patients.
Ross
J S
JS
Department of Pathology and Labortory Medicine, Albany Medical College, Albany, New York 12208, USA. rossj@mail.amc.edu
Cohen
M B
MB
D000230:Adenocarcinoma / Q000737:chemistry / Q000175:diagnosis*; D000951:Antigens, Neoplasm / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis; D003581:Cytodiagnosis; D004273:DNA, Neoplasm / Q000032:analysis; D006801:Humans; D018895:Microsatellite Repeats; D009364:Neoplasm Recurrence, Local / Q000737:chemistry / Q000175:diagnosis; D012680:Sensitivity and Specificity; D019098:Telomerase / Q000032:analysis; D001749:Urinary Bladder Neoplasms / Q000737:chemistry / Q000175:diagnosis*; D019459:Urothelium / Q000737:chemistry / Q000473:pathology
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D019098:Telomerase